Anthera Pharmaceuticals to Report 2015 Second Quarter and Operational Update on August 10
July 30, 2015 17:10 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it plans to issue a press release reporting its 2015 second quarter and operational...
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
July 14, 2015 12:05 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 14, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334...
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
July 09, 2015 09:00 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common...
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
July 08, 2015 16:02 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten...
Anthera Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R) Indexes
June 26, 2015 18:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., June 26, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
Anthera Pharmaceuticals Has Reached Enrollment Target in CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod
June 16, 2015 17:01 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial...
Anthera Pharmaceuticals Announces Additional Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study
June 04, 2015 16:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative...
Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
May 27, 2015 13:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative...
Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update
May 11, 2015 17:30 ET
|
Anthera Pharmaceuticals, Inc.
Completed Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus
Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA...